预约演示

更新于：2025-05-07

Nesidioblastosis

胰岛母细胞增生症

更新于：2025-05-07

基本信息

别名

Familial hyperinsulinaemia with pancreatic nesidioblastosis、Familial hyperinsulinemia with pancreatic nesidioblastosis、HYPERINSULINISM, FAMILIAL, WITH PANCREATIC NESIDIOBLASTOSIS

+ [37]

简介

An inherited autosomal recessive syndrome characterized by the disorganized formation of new islets in the PANCREAS and CONGENITAL HYPERINSULINISM. It is due to focal hyperplasia of pancreatic ISLET CELLS budding off from the ductal structures and forming new islets of Langerhans. Mutations in the islet cells involve the potassium channel gene KCNJ11 or the ATP-binding cassette transporter gene ABCC8, both on CHROMOSOME 11.

关联

项与胰岛母细胞增生症相关的药物

68Ga-NOTA-exendin-4

靶点

GLP-1R

作用机制

GLP-1R激动剂

在研机构

福建医科大学附属第一医院

原研机构-

在研适应症

胰岛素瘤

非在研适应症

胰岛母细胞增生症

最高研发阶段临床1期

首次获批国家/地区-

首次获批日期1800-01-20

项与胰岛母细胞增生症相关的临床试验

JPRN-jRCTs041220114

/ Not yet recruiting临床2期IIT

The single-center phase II study for the efficacy of proton pump inhibitor for postoperative delirium in elderly patients undergoing hepatobiliary and pancreatic surgery

开始日期2023-01-13

申办/合作机构-

ChiCTR2000036342

/ Suspended临床2期IIT

A prospective, single center clinical study of denosumab in the treatment of benign osteolytic tumors in adolescents

开始日期2020-10-01

申办/合作机构

上海长征医院

NCT02560376

/ Unknown status早期临床1期IIT

68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis

This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-NOTA-exendin-4 in insulinoma and nesidioblastosis patients. A single dose of 55.5-111 Mega-Becquerel (MBq) 68Ga-NOTA-exendin-4 will be injected intravenously. Visual and semiquantitative method will be used to assess the PET/CT images.

开始日期2014-02-01

申办/合作机构

北京协和医院

[+1]

100 项与胰岛母细胞增生症相关的临床结果

登录后查看更多信息

100 项与胰岛母细胞增生症相关的转化医学

登录后查看更多信息

0 项与胰岛母细胞增生症相关的专利（医药）

登录后查看更多信息

1,251

项与胰岛母细胞增生症相关的文献（医药）

2025-12-01·Journal of Gastrointestinal Cancer

Initial Application of Fluorescence Imaging for Intraoperative Localization of Small Neuroendocrine Tumors in the Pancreas: Case Report and Review of the Literature

Review

作者: Fang, Xiaosan ; Qian, Daohai ; Shen, Zhengchao ; Zheng, Xingyuan ; Xi, Shihang ; Muhammad, Danish Irshad ; Wang, Xiaoming ; Wang, Guannan ; Wang, Xu ; Jiang, Bin ; Jiang, Yaqi

BACKGROUNDIndocyanine green is commonly used for laparoscopic hepatectomy but remains uncommon in pancreatic surgery. Given the increasing number of small neuroendocrine tumors found in the pancreas and the heavy reliance on laparoscopic ultrasound for intraoperative localization, we attempted to use indocyanine green for these tumors. Our results show good localization and have the potential to provide a valuable clinical aid.CASE PRESENTATIONThis case report details five patients with preoperative diagnosis of pancreatic neuroendocrine tumors of small endocrine tumors, intraoperative successful localization, and successful completion of laparoscopic partial resection of pancreatic tumors by indocyanine green fluorescence staining; none of the patients experienced serious complications after surgery and were discharged from the hospital, and routine pathology confirmed that four cases were pancreatic neuroendocrine tumors of G1 stage, and one case was pancreatic neuroendocrine cell hyperplasia.CONCLUSIONFluorescence imaging technology safely aids in the intraoperative localization of small pancreatic neuroendocrine tumors.

2025-04-01·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease

Pathogenesis and therapeutic effect of sitagliptin in experimental diabetic model of COVID-19

Article

作者: Lawal, Akinkunmi ; Meng, Qinghe ; Wang, Chunyan ; Ma, Julia ; Suo, Liye ; Cooney, Robert N ; Wang, Guirong ; Jacob, Ikechukwu ; Zhao, Wenlu ; Song, Yuqi

This study evaluates the pathogenesis of COVID-19 and the therapeutic efficacy of sitagliptin in diabetic and obese mice. Using a novel double-transgenic mouse model (db/db and K18-hACE2), the findings demonstrates that SARS-CoV-2 infection (Delta variant) causes severe multi-organ damage, glucose metabolism abnormalities, insulin resistance, and pancreatic islet cell damage in diabetic mice. Infected diabetic mice displayed higher mortality, inflammation (elevated TNF-α, IL-6, IL-1β), and fibrinolytic activity (PAI-1), alongside dysregulated diabetes-related hormones (GLP-1, leptin, ghrelin, resistin) compared to non-diabetic controls. Sitagliptin treatment reduced organ injury, hyperglycemia, inflammation, and fibrinolytic activity while improving insulin resistance and glucose metabolism. This was evidenced by decreased fasting blood glucose levels, improved insulin sensitivity, and elevated insulin and GLP-1 levels. These findings suggest sitagliptin is a promising therapeutic strategy to mitigate the severity of COVID-19 in experimental diabetes by modulating inflammation and improving metabolic syndrome. Further mechanistic investigations revealed that the level of hACE2 expression, along with the activation of NF-κB and IRS-1, play critical roles in the development of SARS-CoV-2-induced diabetes, the exacerbation of pre-existing diabetes, and the therapeutic efficacy of sitagliptin.

2025-03-01·Diabetologia

Diet-enhanced LRG1 expression promotes insulin hypersecretion and ER stress in pancreatic beta cells

Article

作者: Smith, Maia R ; Lynch, Jane L ; Wei, Cong ; Bai, Juli ; Hadley, Jason T ; Dong, Lily Q ; Mummidi, Srinivas ; Lopez-Alvarenga, Juan C ; Morales, Desirae D ; Duggirala, Ravindranath ; Ryu, Jiyoon ; Liu, Feng

AIMS/HYPOTHESISUpregulation of serum leucine-rich α-2-glycoprotein 1 (LRG1) has been implicated in diet-induced obesity and metabolic disorders. However, its specific hormonal actions remain unclear. This study aimed to determine whether diet-enhanced serum LRG1 levels promote hyperinsulinaemia by directly stimulating insulin secretion from pancreatic beta cells.METHODSHuman serum samples were obtained from individuals (both male and female) undergoing plastic surgery. Male C57BL/6 wild-type and Lrg1 whole-body knockout (Lrg1^KO) mice were fed a 45% high-fat diet, with serum samples collected every 2 weeks to monitor LRG1 and insulin levels throughout diet-induced obesity. MIN6 beta cells were used to investigate the effects of LRG1 on insulin secretion and intracellular Ca²⁺ release. Antibodies targeting various LRG1 epitopes were used to neutralise LRG1 stimulation in MIN6 cells, and their effectiveness was tested in vivo to assess their ability to prevent LRG1-induced hyperinsulinaemia.RESULTSWe observed a significant positive association between human serum LRG1 levels and both age and BMI, with elevated levels observed in individuals with vs without type 2 diabetes. In mice fed a high-fat diet, LRG1 upregulation in serum was associated with hyperinsulinaemia. Lrg1 knockout protected mice from diet-induced islet hyperplasia and the loss of beta cell mass. Furthermore, neutralising LRG1 activity prevented the onset of diet-induced hyperinsulinaemia and preserved glucose tolerance. Mechanistically, LRG1 induces inositol triphosphate (IP₃) production and intracellular Ca²⁺ release from the endoplasmic reticulum (ER) in a phospholipase C (PLC)-dependent manner, leading to excessive insulin secretion and ER stress in MIN6 beta cells.CONCLUSIONS/INTERPRETATIONIn summary, this study identifies LRG1 as a significant contributor to hyperinsulinaemia and beta cell dysfunction. Targeting LRG1 activity emerges as a promising therapeutic approach for addressing diet-induced beta cell dysfunction and managing type 2 diabetes.

分析

对领域进行一次全面的分析。

或

查看完整样例数据

生物医药百科问答

全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步

立即开始免费试用!

智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。

立即开始数据试用!

智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。